There are 100+ genetically-defined CNS diseases tractable antisense with oligonucleotide (ASO) therapeutics. However, only 7 monogenic CNS diseases have ASOs in development or approved. Genetically defined CNS diseases provide a vast opportunity for new, innovative ASO therapeutics.
Yarrow is developing ASO therapeutics for severe, genetically defined CNS diseases. Yarrow was founded and incubated by RTW team in New York and is rooted in the firm’s longstanding expertise and commitment to solving genetic diseases and oligotherapeutics.
By working closely with the Yarrow team, we look to expand Yarrow’s internal R&D capabilities, in-licence additional assets into the growing pipeline and further capitalize its business and team expansion.